> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Approves Blueprint’s Gavreto for Some Thyroid Cancers
- URL: https://www.fdaweb.com/fda-approves-blueprints-gavreto-for-some-thyroid-cancers/
- Published: 2020-12-02T12:00:00.000Z
- Updated: 2026-09-14T16:38:44.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5148204

FDA has approved an additional indication for Blueprint Medicine’s Gavreto (pralsetinib) to treat patients with advanced or metastatic RET-mutant and RET-fusion-positive thyroid cancer. The company [says](https://www.prnewswire.com/news-releases/blueprint-medicines-announces-fda-approval-of-gavreto-pralsetinib-for-the-treatment-of-patients-with-advanced-or-metastatic-ret-mutant-and-ret-fusion-positive-thyroid-cancer-301183017.html?ref=fdaweb.com) the accelerated approval expands the labeled instructions to include adult and pediatric patients age 12 or older with advanced or metastatic RET-mutant medullary thyroid cancer who require systemic therapy, or with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate).

Earlier this year, FDA granted accelerated approval for Gavreto to treat adults with metastatic RET fusion-positive non-small cell lung cancer as detected by an FDA-approved test.

Blueprint says it is jointly commercializing Gavreto in the U.S. with Genentech.